Loading
institutionsInstitution
Haute Autorité de Santé
France's health technology assessment authority, whose Transparency Committee rates the added clinical benefit of each new cancer drug and so sets its price and reimbursement.
Also called: HASCommission de la Transparence
Overview
Created in 2004, the HAS is an independent public authority that evaluates medicines, devices and procedures for reimbursement and produces clinical guidelines. Its Commission de la Transparence assigns each drug a clinical benefit score (SMR) and an improvement in clinical benefit rating (ASMR I-V) that drive price negotiations with the Comité Économique des Produits de Santé; France's early access programme (accès précoce, formerly ATU) lets patients receive promising cancer drugs before marketing authorisation, with HAS deciding eligibility. HAS also accredits hospitals, runs the screening programme guidance and participates in the EU joint clinical assessments beginning with oncology in 2025.
Location
Saint-Denis, FR
Type
government
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#415 · 12 points (0 Newsweek + 0 NCI + 12 from 6 linked objects) · ranking
- Transparency Committee (SMR / ASMR ratings)
- Early access programme (accès précoce)
- Clinical guidelines and screening guidance
- EU joint clinical assessment participation
Jean Lessi
Director General
Public administrationHealth regulation
Director General of the Haute Autorité de Santé, responsible for the agency's operations since January 2024.
Lionel Collet
President of the Collège
Health technology assessmentHealth policyOtolaryngology
Physician and former university president who chairs the Haute Autorité de Santé, France's health technology assessment and quality body.
Similar pages
- IdeaCopy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data
Shares Gemeinsamer Bundesausschuss / IQWiG, National Institute for Health and Care Excellence, Real-world evidence, Prices and value.
- InstitutionPharmaceutical Benefits Advisory Committee
Shares ISPOR (The Professional Society for Health Economics and Outcomes Research), National Institute for Health and Care Excellence, Real-world evidence, Prices and value.
- InstitutionBundesinstitut für Arzneimittel und Medizinprodukte
Shares Gemeinsamer Bundesausschuss / IQWiG, European Medicines Agency, National Institute for Health and Care Excellence, Prices and value.
- TermAMNOG (Germany, 2011)
Shares France: early access (accès précoce), formerly ATU, EU HTA Regulation (EU) 2021/2282: joint clinical assessments, Gemeinsamer Bundesausschuss / IQWiG, Prices and value.
- InstitutionScottish Medicines Consortium
Shares ISPOR (The Professional Society for Health Economics and Outcomes Research), National Institute for Health and Care Excellence, Real-world evidence, Prices and value.
- InstitutionFondation ARC pour la recherche sur le cancer
Shares Institut Curie, Gustave Roussy, UNICANCER.
- TermHealth technology assessment (HTA), reimbursement and QALYs
Shares Lionel Collet, France: early access (accès précoce), formerly ATU, EU HTA Regulation (EU) 2021/2282: joint clinical assessments, Real-world evidence.
- TermEU pharmaceutical package reform (2023 proposal)
Shares EU HTA Regulation (EU) 2021/2282: joint clinical assessments, European Medicines Agency, Prices and value, Most of the world has almost no cancer care.